Module 1 (KR) — Risk Management Plan (OBX-319)
📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 1 (KR) — Risk Management Plan (OBX-319)
Why it exists. A pharmacovigilance document interpreting the safety data on the schedule regulators expect.
How it is produced here. It is a pharmacovigilance ('drug safety watch') document: it gathers and interprets the simulated safety data on the fixed schedule regulators expect once a drug enters development or the market.
Format & governing standard. —
Module 1 (KR) — Risk Management Plan (OBX-319)
Document ID: M1-KR-RMP
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): MFDS / ICH E2E
Korea (MFDS) Risk Management Plan — OBX-319
Korea-specific RMP for OBX-319: safety specification, pharmacovigilance plan, and risk-minimisation aligned to MFDS expectations and the EU RMP.
Comments (0)
No comments yet. Be the first to say something!